Visit Prostatitis.org    
View unanswered posts | View active topics It is currently Thu Nov 21, 2019 5:57 pm



Reply to topic  [ 2 posts ] 
 Excellent Prostatitis Research by Dr. Jordan Dimitrakov 
Author Message

Joined: Thu Nov 04, 2010 11:12 pm
Posts: 18
Post Excellent Prostatitis Research by Dr. Jordan Dimitrakov
The 501(c) Non-Profit Prostatitis Foundation seeks to support all prostatitis research, unfortunately we do not have the large sums that researchers often need. There is great research than can be done, and there are great researchers passionate about doing the research. Perhaps some private individuals will be inspired to think of ways to fund more prostatitis research. Even the smallest prostatitis research project may require $30,000 or so to get off the ground.

The Prostatitis Foundation financed some of Dr. Dimitrakov's early travels to prostatitis meetings and workshops, and we are fortunate that he has now settled in the USA to do prostatitis research. The problem for prostatitis researchers is getting all the financing they need to do all their research projects.

If anyone does not understand anything about the abstracts below simply reply and post your questions and we will answer as best we can. Other researchers will be profiled soon as well.

1. Nat Rev Urol. 2010 Mar;7(3):127-35. Epub 2010 Feb 9.
New treatments for chronic prostatitis/chronic pelvic pain syndrome.
Strauss AC, Dimitrakov JD.
Harvard Medical School, Children's Hospital Boston, Enders Research Building, Room 1061, 300 Longwood Avenue, Boston, MA 02115, USA.

Abstract

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition among men of a wide age range, with detrimental effects on quality of life. The etiology, pathogenesis, and optimal treatment of CP/CPPS remain unknown, although progress has been made in these domains in recent years. A wide variety of pharmacologic and nonpharmacologic therapies have been studied in clinical trials, but most have shown limited efficacy in symptom alleviation. CP/CPPS is increasingly viewed as a condition that involves variable degrees of neuropathic pain. Medications such as gabapentin, pregabalin, memantine, and tricyclic antidepressants are often used in other neuropathic pain conditions and, therefore, are considered potential treatments for CP/CPPS. Few studies of these agents in patients with CP/CPPS have been reported, but future clinical trials should help to determine their utility and to characterize the pathogenetic mechanisms of pain in CP/CPPS. Combining treatment trials with biomarker, genomic, and imaging studies, in addition to epidemiologic and symptom-based assessments, will maximize the ability to probe disease etiology and pathogenesis, as well as identify effective treatment.

2. Folia Med (Plovdiv). 2009 Jul-Sep;51(3):42-4.
Urologic chronic pelvic pain syndrome--looking back and looking forward.
Dimitrakov J, Dimitrakova E.
Urological Diseases Research Center, Harvard Medical School, Children's Hospital, Boston, USA. Jordan.Dimitrakov@childrens.harvard.edu

Urologic chronic pelvic pain syndrome (UCPPS) is a symptom-based umbrella term for interstitial cystitis/painful bladder syndrome (IC/PBS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men. Unfortunately, no gold standard for diagnosis or treatment of UCPPS exists. We review several emerging theories on the etiology and pathogenesis of UCPPS with a special emphasis on genomic and proteomic technologies. We also propose a systems-biology approach to elucidating the pathogenetic mechanisms implicated in UCPPS and the discovery and validation of new biomarkers for UCPPS. Using data gleaned from high-throughput genomic and proteomic screens can help develop effective treatments for this enigmatic chronic pelvic pain syndrome.

PMID: 19957562

3. J Urol. 2009 Nov;182(5):2123-31. Epub 2009 Sep 16.
Evidence for overlap between urological and nonurological unexplained clinical conditions.
Rodríguez MA, Afari N, Buchwald DS; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain.
Collaborators (14)
Afari N, Buchwald DS, Clauw D, Dimitrakov J, Kusek J, Mullins C, Nyberg L, Payne C, Peñacoba C, Pezzone M, Pontari M, Potts J, Rodríguez MA, Warren J.
Department of Psychology, University Rey Juan Carlos, Madrid, Spain.

Abstract

PURPOSE: Unexplained clinical conditions share common features such as pain, fatigue, disability out of proportion to physical examination findings, inconsistent laboratory abnormalities, and an association with stress and psychosocial factors. We examined the extent of the overlap among urological and nonurological unexplained clinical conditions characterized by pain. We describe the limitations of previous research and suggest several possible explanatory models.

MATERIALS AND METHODS: Using hallmark symptoms and syndromes as search terms a search of 12 databases identified a total of 1,037 full-length published articles in 8 languages from 1966 to April 2008. The search focused on the overlap of chronic pelvic pain, interstitial cystitis, painful bladder syndrome, chronic prostatitis/chronic pelvic pain syndrome or vulvodynia with fibromyalgia, chronic fatigue syndrome, temporomandibular joint and muscle disorders or irritable bowel syndrome. We abstracted information on authorship, type of case and control groups, eligibility criteria, case definitions, study methods and major findings.

RESULTS: The literature suggests considerable comorbidity between urological and nonurological unexplained clinical conditions. The most robust evidence for overlap was for irritable bowel syndrome and urological unexplained syndromes with some estimates of up to 79% comorbidity between chronic pelvic pain and symptoms of irritable bowel syndrome. However, most studies were limited by methodological problems, such as varying case definitions and selection of controls.

CONCLUSIONS: The overlap between urological and selected nonurological unexplained clinical conditions is substantial. Future research should focus on using standardized definitions, and rigorously designed, well controlled studies to further assess comorbidity, clarify the magnitude of the association and examine common pathophysiological mechanisms.

PMID: 19758633

4. Analyst. 2009 Jun;134(6):1133-7. Epub 2009 Apr 16.
A candidate serum biomarker for bladder pain syndrome/interstitial cystitis.
Rubio-Diaz DE, Pozza ME, Dimitrakov J, Gilleran JP, Giusti MM, Stella JL, Rodriguez-Saona LE, Buffington CA.
Department of Food Science and Technology, College of Food, Agriculture and Environmental Sciences, The Ohio State University, Columbus, Ohio, USA.

Abstract

Reliable diagnostic markers for Bladder Pain Syndrome/Interstitial Cystitis (IC) currently are not available. This study evaluated the feasibility of diagnosing IC in humans and domestic cats from the spectra of dried serum films (DSFs) using infrared microspectroscopy. Spectra were obtained from films from 29 humans and 34 domestic cats to create classification models using Soft Independent Modeling by Class Analogy (SIMCA). Ultrafiltration of serum improved discrimination capability. The classification models for both species successfully classified spectra based on condition (healthy/sick), and a different set of masked spectra correctly predicted the condition of 100% of the subjects. Classification required information from the 1500-1800 cm(-1) spectral region to discriminate between subjects with IC, other disorders, and healthy subjects. Analysis of cat samples using liquid chromatography-mass spectroscopy revealed differences in the concentration of tryptophan and its metabolites between healthy and affected cats. These results demonstrate the potential utility of infrared microspectroscopy to diagnose IC in both humans and cats.

PMID: 19475139


5. J Urol. 2009 Apr;181(4):1550-7. Epub 2009 Feb 23.
Genetics and phenotyping of urological chronic pelvic pain syndrome.
Dimitrakov J, Guthrie D.
George O'Brien Center for Urological Diseases Research, Harvard Medical School and Children's Hospital Boston, Boston, Massachusetts, USA.

Abstract

PURPOSE: Interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome, collectively renamed urological chronic pelvic pain syndromes, are a group of medically unexplained physical symptoms. Diagnosis depends on excluding all possible causes of pain and treatment targets symptoms alone. An emerging body of research implicates systemic factors in the pathogenesis of urological chronic pelvic pain syndromes including abnormal sympathetic nervous system and hypothalamic-pituitary-adrenal axis activity. Several new lines of evidence also suggest a genetic component to disease pathogenesis. Despite ongoing efforts, neither effective treatments nor mechanistic understanding of the pathogenesis of urological chronic pelvic pain syndromes exists.

MATERIALS AND METHODS: We performed a survey of the available literature on urological chronic pelvic pain syndromes. We reviewed recent research implicating genetic mechanisms in the development of urological chronic pelvic pain syndromes to find a systematic approach of rigorous phenotyping on which to base further investigation of these chronic pain conditions.

RESULTS: Three studies revealed identifying genetic risk factors for disease. In addition, increasing lines of evidence of familial clustering and twin studies suggested a genetic basis for disease.

CONCLUSIONS: Given the success of genome-wide association studies in quantifying genetic risk in several polygenic diseases, we suggest a similar genome-wide approach to the study of urological chronic pelvic pain syndromes. As genome-wide association studies depend on carefully defined patient populations, we provide an outline for a thorough and multidisciplinary characterization of patient phenotypes. Although urological chronic pelvic pain syndromes continue to mystify clinicians and researchers alike, we believe the powerful new methods of unbiased interrogation of the whole genome based on systematically grouped patients possess enormous potential for progress in treating and understanding this disease.

PMID: 19230927

6. J Urol. 2008 May;179(5):1660-1. Epub 2008 Mar 17.
A road map to biomarker discovery and validation in urological chronic pelvic pain syndrome.
Dimitrakov J.

PMID: 18343423


7. Urology. 2008 Feb;71(2):353.
Re: Nadler RB, McNaughton Collins M, Propert KJ, et al: Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome (Urology 67: 337-342, 2006).

Dimitrakov JD.


8. Urology. 2008 Feb;71(2):261-6.
Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome.
Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC.
Harvard Urological Diseases Research Center, Children's Hospital Boston, Boston, Massachusetts 02115, USA. Jordan.Dimitrakov@childrens.harvard.edu

Abstract

OBJECTIVES: To identify adrenocortical hormone abnormalities as indicators of endocrine dysfunction in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

METHODS: We simultaneously measured the serum concentrations of 12 steroids in patients with CP/CPPS and controls, using isotope dilution liquid chromatography, followed by atmospheric pressure photospray ionization and tandem mass spectrometry.

RESULTS: We evaluated 27 patients with CP/CPPS and 29 age-matched asymptomatic healthy controls. In the mineralocorticoid pathway, progesterone was significantly greater, and the corticosterone and aldosterone concentrations were significantly lower, in the patients with CP/CPPS than in the controls. In the glucocorticoid pathway, 11-deoxycortisol was significantly lower and the cortisol concentrations were not different between the patients and controls. In the sex steroid pathway, the androstenedione and testosterone concentrations were significantly greater in those with CP/CPPS than in the controls. The estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate concentrations were not different between the patients and controls. The National Institutes of Health-Chronic Prostatitis Symptom Index total and pain domain scores correlated positively with the 17-hydroxyprogesterone and aldosterone (P <0.001) and negatively with the cortisol (P <0.001) concentrations.

CONCLUSIONS: Our results suggest reduced activity of CYP21A2 (P450c21), the enzyme that converts progesterone to corticosterone and 17-hydroxyprogesterone to 11-deoxycortisol. Furthermore, these results provide insights into the biologic basis of CP/CPPS. Follow-up studies should explore the possibility that patients with CP/CPPS meet the diagnostic criteria for nonclassic congenital adrenal hyperplasia and whether the hormonal findings improve or worsen in parallel with symptom severity.


9. Arch Intern Med. 2007 Oct 8;167(18):1922-9.
Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review.
Dimitrakov J, Kroenke K, Steers WD, Berde C, Zurakowski D, Freeman MR, Jackson JL.
Harvard Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Jordan.Dimitrakov@childrens.harvard.edu

Erratum in:

* Arch Intern Med. 2007 Dec 10-22;167(22):2452.

Abstract

BACKGROUND: More than 180 different types of therapy have been used in the treatment and management of painful bladder syndrome/interstitial cystitis (PBS/IC), yet evidence from clinical trials remains inconclusive. This study aimed to evaluate the efficacy of pharmacologic approaches to PBS/IC, to quantify the effect size from randomized controlled trials, and to begin to inform a clinical consensus of treatment efficacy for PBS/IC.

METHODS: We identified randomized controlled trials for the pharmacologic treatment of patients with PBS/IC diagnosed on the basis of National Institute of Diabetes and Digestive and Kidney Diseases or operational criteria. Study limitations include considerable patient heterogeneity as well as variability in the definition of symptoms and in outcome assessment.

RESULTS: We included a total of 1470 adult patients from 21 randomized controlled trials. Only trials for pentosan polysulfate sodium had sufficient numbers to allow a pooled analysis of effect. According to a random-effects model, the pooled estimate of the effect of pentosan polysulfate therapy suggested benefit, with a relative risk of 1.78 for patient-reported improvement in symptoms (95% confidence interval, 1.34-2.35). This result was not heterogeneous (P = .47) and was without evidence of publication bias (P = .18). Current evidence also suggests the efficacy of dimethyl sulfoxide and amitryptyline therapy. Hydroxyzine, intravesical bacille Calmette-Guérin, and resiniferatoxin therapy failed to demonstrate efficacy, but evidence was inconclusive owing to methodological limitations.

CONCLUSIONS: Pentosan polysulfate may be modestly beneficial for symptoms of PBS/IC. There is insufficient evidence for other pharmacologic treatments. A consensus on standardized outcome measures is urgently needed.

PMID: 17923590

10. FEBS Lett. 2007 Aug 7;581(20):3795-9. Epub 2007 Jul 2.
p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells.
Kim J, Keay SK, Dimitrakov JD, Freeman MR.
The Urological Diseases Research Center, Children's Hospital Boston, Boston, MA 02115, USA.

Abstract

Antiproliferative factor (APF) is a sialoglycopeptide elevated in the urine of patients with interstitial cystitis, a urinary bladder disorder of unknown etiology that is characterized by chronic pelvic pain. The present study was directed toward uncovering a pathway through which APF signals. Treatment of human urothelial cells with native APF resulted in growth inhibition accompanied by blockade of cell cycle transit and increased p53. Reduced expression of p53 by RNA interference diminished, while ectopic expression of p53 mimicked, the effects of APF. These are the first findings implicating the network of p53 target genes in urothelial defects associated with interstitial cystitis.

11. Urology. 2006 Sep;68(3):463-9.
Drug delivery systems in urology--getting "smarter".
Farokhzad OC, Dimitrakov JD, Karp JM, Khademhosseini A, Freeman MR, Langer R.
Department of Anesthesiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
PMID: 17010721

12. Urology. 2006 May;67(5):881-8.
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR.
Harvard Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. Jordan.Dimitrakov@childrens.harvard.edu

13. N Engl J Med. 2006 May 4;354(18):1950-1; author reply 1950-1.
Saw palmetto for benign prostatic hyperplasia.
Dimitrakov JD.
Comment on:

* N Engl J Med. 2006 Feb 9;354(6):557-66.

14. APMIS. 2005 Jul-Aug;113(7-8):564-7.
Nonspecific granulomatous prostatitis with calculous ductal ectasia and extensive Paneth cell-like epithelial metaplasia. Case report.
Dikov D, Vassilev I, Dimitrakov J.
Service d'Anatomie Pathologique, Centre Hospitalier de Lagny-Marne-La-Vallée, Lagny-sur-Marne, France. ddikov@ch-lagny77.fr

Abstract

We present a case of nonspecific granulomatous prostatitis in combination with calculous ductal ectasia and extensive epithelial Paneth cell-like metaplasia in a TURP-specimen. Our report highlights the importance of calculous ductal obstruction and stasis of secretions in the etiopathogenesis of this type of prostatitis. The observed extensive Paneth cell-like metaplastic change in adjacent epithelial cells most likely represents a phenotypic adaptive mechanism directed against foreign antigens and nondegradable lipids in the stagnant intraluminal debris.

15. Int J Surg Pathol. 2005 Apr;13(2):227-31.
Pathologic features of necrotizing adenoviral prostatitis in an AIDS patient.
Dikov D, Chatelet FP, Dimitrakov J.
Department of Pathology, Hospital Lagny-Marne-La-Valée, Paris, France.

Abstract

Adenovirus has been implicated as a cause of opportunistic infections in immunocompromised patients, frequently with multiorgan involvement and a fatal outcome. We describe a case of necrotizing adenoviral prostatitis in a 35-year-old man with terminal AIDS and generalized adenoviral infection. The histopathologic findings of intraacinar necrotizing inflammation, prominent viral nuclear inclusions in residual epithelium, and mild T-lymphocyte and macrophageal inflammatory reaction were observed in the prostate. The presence of adenovirus was confirmed by electron microscopy and immunohistochemistry. Squamous metaplasia was present in the surrounding acini. This case of adenoviral prostatitis appears to be the first report of its kind in medical literature and demonstrates another aspect of the diversity of organ manifestations seen in this infection. This lesion should be included in the differential diagnosis of necrotizing prostatic diseases.

PMID: 15864391

16. Folia Med (Plovdiv). 2004;46(1):19-21.
Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia.
Dimitrakova ED, Dimitrakov JD, Karumanchi SA, Pehlivanov BK, Milchev NP, Dimitrakov DI.
Clinic of Obstetrics and Gynecology, Medical University - Plovdiv, Bulgaria.

Erratum in:

* Folia Med (Plovdiv). 2004;46(3):67. Karumanchi, SG [corrected to Karumanchi, SA].

Abstract

The pathophysiology of preeclampsia remains largely unknown. A number of circulating placenta-produced factors have been implicated in causing the endothelial dysfunction and the clinical phenotype characteristic of preeclampsia. AIM: Determination of serum levels of placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Eleven pregnant women with preeclampsia and 11 healthy women (controls) were included in the study. Determination of sFlt-1 was done with ELISA. The mean serum sFlt-1 levels of pregnant women with preeclampsia were twice as high as that of women with normal pregnancy. The highest level of sFlt-1 was found in women with severe preeclampsia. In women with mild form of preeclampsia the sFlt-1 level was close to that of the controls. sFlt-1 appears to be involved in the pathogenesis of preeclampsia and its serum levels can be used as a diagnostic marker of preeclampsia.

17. Folia Med (Plovdiv). 2004;46(1):15-8.
Effect of mycophenolate mofetil (Cell Cept) in the treatment of immune glomerulopathies.
Dimitrakov DJ, Nikolov DG, Dimitrakov JD, Despotov TB, Kumchev EP, Tzvetkova ZS, Tilkian EE, Pandeva SM, Chatalbasheva DL, Tzekov VD, Anavi BL.
II-nd Department of Internal Medicine, Medical University - Plovdiv, Bulgaria.

Abstract

AIM: To study the effect of mycophenolate mofetil (Cell Cept) in treating patients with various types of chronic glomerulonephritis and other immune nephropathies.

MATERIAL AND METHODS: Between 2000 and 2003 we treated 35 patients (18 women, 17 men) with Cell Cept (La Roche). In 32 patients the diagnosis was confirmed by kidney biopsy (immunofluorescence, light and electron microscopy).

RESULTS: Treatment with Cell Cept was very successful in 22 of the patients in the study (62.86%). Proteinuria was significantly reduced and firmly maintained well below 0.5 g/l; serum protein levels were elevated to normal values, the edemas disappeared. In 12 patients the drug had a good effect: there was a significant reduction of proteins in the urea within 1.2 - 2.0 g/l, an increase of total protein and albumins in plasma but after three months of treatment. The therapy was with no effect only in one patient with primary amyloidosis of kidneys.

CONCLUSIONS: Treatment with mycophenolate mofetil (Cell Cept) is an alternative modality for the management of immune glomerulopathies resistant to conventional and pulse pathogenetic therapeutic regimens. It can be a treatment of first choice.

18. Folia Med (Plovdiv). 2003;45(1):5-7.
Autosomal recessive polycystic kidney disease. Clinical and genetic profile. (Review and a case report).
Dimitrakov JD, Dimitrakov DI.
Department of Nephrology, Medical University, Plovdiv, Bulgaria.

Abstract

BACKGROUND: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder inherited in a recessive manner. The ARPKD gene is located on chromosome 6. The disease is characterised by specific changes in the kidney and liver.

AIM: To make a review of modern achievements in studying the clinical, genetic and diagnostic problems concerning ARPKD and contribute an illustrative case.

RESULTS: We reviewed modern research on the molecular genetics of autosomal recessive polycystic kidney disease related to PKHD1 gene located on chromosome 6p21-cen, as well as on the role of fibrocystin in the terminal differentiation of the collecting and biliary ductules. The clinical manifestations of the disease in infancy and in early childhood are analysed. A diagnostic algorithm is proposed incorporating both clinical and genetic methods. The illustrative case we reported of a 22-year-old patient with ARPKD supports the view that the disease occurs, though rarely, later than in childhood.

CONCLUSION: The authors recommend that in cases with late manifestation of the disease in adolescence with chronic renal failure, possibilities be searched for extracorporeal replacement (renal transplantation) when this is allowed by the complications associated with the congenital liver fibrosis.

19. Folia Med (Plovdiv). 2002;44(4):10-2.
Ten-year clinical and ultrasonographic follow-up of siblings from families with autosomal dominant polycystic kidney disease.
Dimitrakov DY, Dimitrakov JD, Despotov TB.
Medical University Plovdiv, Clinic of Nephrology, Bulgaria.

Abstract

We conducted a ten-year clinical and ultrasound follow-up study of 120 siblings with ADPKD (68 men and 52 women, aged 19-40). 40 subjects had polycystic kidney disease. During the study period, the number and size of the cysts increased. Symptoms and signs also changed: at baseline 51% of the subjects were asymptomatic dropping subsequently to 2%. Initially, 32 subjects had 1-5 cysts in one or both kidneys and they were classified as suspected of having ADPKD. Significant changes were found in this group at the end of the follow-up. In 12 of them (37.50%) subsequent ultrasonograms revealed an increase in the number and size of the cysts--i.e. evolution towards ADPKD. None of the subjects in this group had a decrease in the number of cysts. In the control group, three had multiple cysts but most subjects were ultrasonographically negative for polycystic kidney disease. In conclusion, the authors recommend a clinical and ultrasonographic long-term follow-up of subjects at risk for ADPKD which should allow early diagnosis as well as prevention of the complications which result in chronic renal failure.

20. Am J Surg Pathol. 2003 May;27(5):700-2.
Hyaline globules (thanatosomes) in prostate disease.
Dikov D, Roland J, Chatelet FP, Cywiner-Golenzer C, Dimitrakov J.
Comment on:

* Am J Surg Pathol. 2002 Feb;26(2):237-43.

PMID: 12717257


Sat Jan 22, 2011 2:31 pm
Profile

Joined: Tue Jul 26, 2011 8:12 pm
Posts: 1
Post Re: Excellent Prostatitis Research by Dr. Jordan Dimitrakov
so i see the abstracts. however, what does this mean for me, the non bacterial chronic prostatitis sufferer who cannot get any help from the urologists that dont understand this affliction?


Tue Jul 26, 2011 9:14 pm
Profile
Display posts from previous:  Sort by  
Reply to topic   [ 2 posts ] 

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to:  
cron
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group.
Designed by STSoftware for PTF.